Response on " RE: Cost-effectiveness of pertussis booster vaccination in the Netherlands"

Vaccine

Volumn 31, Issue 16, 2013, Pages 2024-

  Rozenbaum, Mark H ^a   Postma, Maarten J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PERTUSSIS VACCINE;

CANCER PREVENTION; COST EFFECTIVENESS ANALYSIS; HUMAN; LETTER; PERTUSSIS; PRIORITY JOURNAL; PRODUCTIVITY; UTERINE CERVIX CANCER; VACCINATION;

FEMALE; HUMANS; IMMUNIZATION, SECONDARY; MALE; PERTUSSIS VACCINE; WHOOPING COUGH;

EID: 84875542226     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.11.082     Document Type: Letter

References (5)

1. Rozenbaum M.H., De C.E., Postma M.J. Cost-effectiveness of pertussis booster vaccination in the Netherlands. Vaccine 2012, June.
2. Rozenbaum M.H., De Cao Westra T.A., Postma M.J. Dynamic models for health economic assessments of pertussis vaccines; what goes around comes around.... Expert Rev Vaccines 2012, 11(12).
3. National, state, and local area vaccination coverage among children aged 19-35 months - United States, 2008. MMWR Morb Mortal Wkly Rep 2009, 58(August (33)):921-926.
4. Westra T.A., Parouty M., Brouwer W.B., Beutels P.H., Rogoza R.M., Rozenbaum M.H., et al. On discounting of health gains from human papillomavirus vaccination: effects of different approaches. Value Health 2012, 15(May (3)):562-567.
5. Bos J.M., Postma M.J., Annemans L. Discounting health effects in pharmacoeconomic evaluations: current controversies. Pharmacoeconomics 2005, 23(7):639-649.